The projected annual revenue for Mayne Pharma Group is 428MM, an increase of 132.88%. The projected annual non-GAAP EPS is -0.56.
If analysts give a stock an overweight rating, they expect the stock to outperform its industry in the market. Analysts may give a stock an overweight recommendation due to a steady stream of positive news, good earnings, and raised guidance.
As of August 31, 2023, the average one-year price target for Mayne Pharma Group is 4.43. The forecasts range from a low of 3.84 to a high of $5.04. The average price target represents a decrease of 6.73% from its latest reported closing price of 4.75
The projected annual revenue for Mayne Pharma Group is 428MM, an...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.08 |
Change
0.010(0.20%) |
Mkt cap ! $412.7M | |||
| Open | High | Low | Value | Volume |
| $5.05 | $5.08 | $5.02 | $395.8K | 78.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $5.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.08 | 3084 | 3 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| MYX (ASX) Chart |